Table 3. Cost-effectiveness of Voriconazole Versus Fluconazole in Patients With Allogeneic Hematopoietic Cell Transplants, 12-Month Outcomes.
| Total Study Population | AML Subpopulation | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Outcome | Voriconazole | Fluconazole | Difference | Voriconazole | Fluconazole | Difference |
| Clinical outcomes | ||||||
| IFI events | 0.127 | 0.137 | -0.011 | 0.145 | 0.228 | -0.083 |
| Life-years | 8.219 | 8.269 | -0.05 | 7.911 | 6.891 | 1.020 |
| Costsa | ||||||
| Planned prophylaxis | $9,774 | $1,104 | $8,670b | $10,142 | $990 | $9,152b |
| Other prophylaxis | $3,162 | $1,165 | $1,997 | $2,809 | $897 | $1,911 |
| Empirical therapy | $1,744 | $2,284 | -$540 | $1,805 | $2,400 | -$595 |
| IFI treatment | $6,870 | $8,278 | -$1,408 | $8,164 | $13,070 | -$4,906 |
| Total | $21,549 | $12,831 | $8,718b | $22,919 | $17,358 | $5,562 |
| Incremental cost-effectiveness ratios | ||||||
| Incremental cost per IFI avoided | $812,990 | $66,919 | ||||
| Incremental cost per life-year gained | Dominatedc | $5,453 | ||||
AML = acute myeloid leukemia; IFI = invasive fungal infection.
a
Costs in 2011 US$.
b
95% confidence limits estimated using the bootstrap analysis do not include zero.
c
Dominated means that treatment with voriconazole was both more expensive and resulted in fewer estimated life years than treatment with fluconazole.